DPI and Amethis Co-Invest in Marcyrl
Development Partners International (DPI) and Amethis have co-invested in Marcyrl Pharmaceutical Industries, an Egyptian pharmaceuticals manufacturer focused on specialty generics.
The investment is aimed at accelerating the Company’s ambition to drive greater access to critical care drugs across Africa.
Ziad Abaza, Managing Director at Development Partners International said: “By leveraging its first mover advantage in critical specialty areas of the pharmaceutical sector, Marcyrl has carved out a unique position for itself in the market, recognised as a trusted partner in Egypt for delivery of specialty generics.”
“Combining the entrepreneurial mindset of the Marcyrl management team with the company’s deep heritage of innovation, the business has a significant runway for growth, with strong foundations in Egypt, and a scalable platform well positioned to expand its distribution and export network across the continent. We look forward to working with the Marcyrl team to support the business in this next phase of growth.”
Marcyrl, established in 1998, is a manufacturer of essential pharmaceuticals, focused on improving accessibility to specialty generics drugs in Egypt.
Since founding, the business has seen significant growth with resilient sales, demonstrated by a strong performance in the past year, with revenues representing more than 2% market share of the Egyptian market.
Central to Marcyrl’s ambition is improving access to specialty pharmaceuticals in Egypt and across Africa through its international export network.
To achieve this, the company is investing and innovating in its product portfolio, expanding into new specialty areas such as new hormonal therapy treatments, which it added to its portfolio in 2016.
Marcyrl has also demonstrated its first mover ability in key areas of the market, in 2015 becoming the first company to produce and launch its antiviral product portfolio, highly effective treatments for Hepatitis C that allowed Marcyrl to access the tender market.